Natalie May - Incannex Healthcare Head Operations
| IXHL Stock | USD 1.53 0.36 19.05% |
Executive
Natalie May is Head Operations of Incannex Healthcare Ltd
| Address | 8 Century Circuit, Sydney, NSW, Australia, 2153 |
| Phone | 61 4 0984 0786 |
| Web | https://www.incannex.com |
Incannex Healthcare Management Efficiency
The company has return on total asset (ROA) of (0.5697) % which means that it has lost $0.5697 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.1522) %, meaning that it created substantial loss on money invested by shareholders. Incannex Healthcare's management efficiency ratios could be used to measure how well Incannex Healthcare manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return On Tangible Assets is estimated to slide to -1.31. Return On Capital Employed is expected to rise to -2.87 this year. At this time, Incannex Healthcare's Total Current Assets are quite stable compared to the past year. Other Current Assets is expected to rise to about 12.5 M this year, although the value of Non Current Assets Total will most likely fall to about 722.5 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Glenn David | Phibro Animal Health | 53 | |
| Ori Gutwerg | ANI Pharmaceuticals | 51 | |
| Christine CPA | Prestige Brand Holdings | 49 | |
| Christopher Mutz | ANI Pharmaceuticals | 54 | |
| James Marken | ANI Pharmaceuticals | 61 | |
| MD FAAFP | Collegium Pharmaceutical | 64 | |
| Christopher MD | Collegium Pharmaceutical | N/A | |
| YatPui Au | Regencell Bioscience Holdings | 51 | |
| Chad Gassert | ANI Pharmaceuticals | 49 | |
| Antonia Assang | Regencell Bioscience Holdings | N/A | |
| Richard Johnson | Phibro Animal Health | 75 | |
| Tien Chau | Regencell Bioscience Holdings | 54 | |
| Jose Vieira | Procaps Group SA | 59 | |
| Larry Miller | Phibro Animal Health | 61 | |
| Carlos Russo | Procaps Group SA | 39 | |
| Krista Davis | ANI Pharmaceuticals | 51 | |
| Mary Fritz | Prestige Brand Holdings | N/A | |
| Camilo Camacho | Procaps Group SA | 51 | |
| Thomas Rowland | ANI Pharmaceuticals | 57 | |
| Bart Dunn | Collegium Pharmaceutical | N/A | |
| Daniel Bernal | Procaps Group SA | N/A | |
Management Performance
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.57 |
Incannex Healthcare Leadership Team
Elected by the shareholders, the Incannex Healthcare's board of directors comprises two types of representatives: Incannex Healthcare inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Incannex. The board's role is to monitor Incannex Healthcare's management team and ensure that shareholders' interests are well served. Incannex Healthcare's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Incannex Healthcare's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Mark Bleackley, Head Officer | ||
| BSc EMBA, Chief IncannexTM | ||
| Joseph Swan, Treasurer CFO | ||
| Rosemarie Walsh, VP Board | ||
| Madhukar FCIS, CFO Secretary | ||
| Lekhram MSc, Chief Officer | ||
| Madhukar Bhalla, CFO Sec | ||
| Joel Latham, CEO President | ||
| Natalie May, Head Operations | ||
| Luigi MD, Chief Officer |
Incannex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Incannex Healthcare a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.15 | ||||
| Return On Asset | -0.57 | ||||
| Operating Margin | (538.33) % | ||||
| Current Valuation | 29.8 M | ||||
| Shares Outstanding | 17.64 M | ||||
| Shares Owned By Insiders | 25.86 % | ||||
| Shares Owned By Institutions | 4.13 % | ||||
| Number Of Shares Shorted | 62.36 K | ||||
| Price To Book | 5.08 X | ||||
| Price To Sales | 2,793 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Incannex Healthcare Ltd. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Incannex Healthcare. If investors know Incannex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Incannex Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.36) | Revenue Per Share | Quarterly Revenue Growth 0.296 | Return On Assets | Return On Equity |
The market value of Incannex Healthcare is measured differently than its book value, which is the value of Incannex that is recorded on the company's balance sheet. Investors also form their own opinion of Incannex Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Incannex Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Incannex Healthcare's market value can be influenced by many factors that don't directly affect Incannex Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Incannex Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Incannex Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Incannex Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.